Gene Therapy for Inherited Deafness Provides Lasting Hearing Restoration
A multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
Tag: gene therapy
All
Latest
All
Latest
Ear Science Institute Australia Developing Biobank to Advance Genetic Therapies for Hearing Loss
Ear Science Institute Australia is launching a biobank for genetic-associated hearing loss to advance personalized therapies and treatments.
All
Latest
Steps Forward in Hearing Loss Gene Therapy Linked to Rare Disease
Researchers have developed in mice a gene therapy that significantly reduces the hearing loss associated with Norrie disease.
OSU Researchers Study Otoferlin Mutations
Researchers have found a new piece of the puzzle in the quest to use gene therapy to enable people born deaf to hear. The work centers around a large gene responsible for a mutation in the inner-ear protein, otoferlin, which is linked to severe congenital hearing loss.
Read More
UPenn Researchers ID New Cause of Hearing Loss
A gene called GAS2 plays a key role in normal hearing, and its absence causes severe hearing loss, according to a study led by researchers in the Perelman School of Medicine at the University of Pennsylvania.
Read More
Sensorion Announces Gene Therapy Collaboration
Sensorion announced the addition of a new gene therapy target, GJB2 coding for the Connexin 26 protein, to its development portfolio. The target is the third candidate to emerge from Sensorion’s R&D collaboration with Institut Pasteur, according to Sensorion.
Read More
TAU Scientists Develop Gene Therapy for Deafness
A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material “replaces” the genetic defect and enables the cells to continue functioning normally.
Read More
Sonova to Acquire 3.7% Ownership Stake in Sensorion
Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announced that Sonova Holding AG will acquire a 3.7% ownership stake in Sensorion by way of subscription to a reserved share capital increase for total gross proceeds of €5 million (USD $6.08 million).
Read More
‘Common Inherited Genetic Variant’ Identified as Frequent Cause of Adult Deafness
While the particular manifestations of this genetically induced hearing loss varied, as did the age at which hearing problems began, its prevalence suggests that it is common (highly penetrant) and that many thousands of people might be at risk of deafness as a result, explain the researchers.
Read More
Sensorion Appoints Géraldine Honnet as Chief Medical Officer; Juergen Heitmann as Chief Business Officer
Honnet is a medical doctor and joins the company from Généthon, where she spent nine years as Chief Medical Officer, overseeing international gene therapy clinical trials in multiple rare diseases.
Read More
Akouos Launches Sing Registry to Track Genetic Changes in Hearing, Treatments
The Sing Registry is a new, observational research study focused on understanding the lifelong impact of genetic sensorineural hearing loss (SNHL), according to the company.
Read More
Akouos Announces Gene Therapy to Treat Genetic Hearing Loss
AK-OTOF is intended to treat individuals with sensorineural hearing loss due to mutations in the OTOF gene, who typically have severe hearing loss in both ears from birth, by promoting the expression of normal, functional otoferlin protein in affected cells of the cochlea.
Read More
Sensorion Appoints John Furey As Independent Board Member
Furey was most recently Chief Operating Officer (COO) for Spark Therapeutics, a global gene therapy developer. This appointment will be effective at the next meeting of the board of directors of the company, in September 2019.
Read More
Sensorion Awarded $11 Million Research Grant for Congenital Deafness
The aim of this project is to develop a specific gene therapy program aimed at correcting an inherited monogenic form of deafness caused by a mutation in the gene encoding for the Otoferlin protein (DNBF9).
Read More
Sensorion Awarded $11 Million Research Grant for Congenital Deafness
The aim of this project is to develop a specific gene therapy program aimed at correcting an inherited monogenic form of deafness caused by a mutation in the gene encoding for the Otoferlin protein (DNBF9).
Read More
Sensorion Partners with Institut Pasteur on Research Framework Targeting Hearing Loss
Sensorion and Institut Pasteur have leveraged the last six months to reach a partnership framework agreement. This agreement provides for, after completion of a research program, an exclusive option to obtain licenses.
Read More
Cold Spring Harbor Laboratory Press Releases ‘Function and Dysfunction of the Cochlea’
The book describes major advances in our understanding of the pathogenic processes underlying various forms of hearing loss and the emergence of treatments for deafness.
Read More
Researchers Restore Hearing via Gene Therapy in Deaf Mouse Model
Researchers have managed to restore hearing in an adult mouse model of DFNB9 deafness, a hearing disorder that represents one of the most frequent cases of congenital genetic deafness
Read More